Ancrod in acute stroke
Last reviewed 01/2018
Ancrod converts fibrinogen into soluble fibrin products, there by decreasing serum fibrinogen and reducing its use in thrombus formation.
In a trial of 500 patients, randomised to receive either Ancrod or placebo within 3 hours, 42% of patients given Ancrod had a total or near-total recovery compared to 34% in the placebo group.